Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-II Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This clinical trial examines how a mutation in HSD3B1 (1245C) gene affects treatment of stage
I-III breast cancer. This trial may help researchers determine if mutations in HSD3B1
decreases the efficacy of aromatase inhibitor therapy such as letrozole. Letrozole may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth.